World ADC Conference Series
Recently, we have seen a wave of breakthroughs and approvals in the antibody-drug conjugates space. Keeping pace with the field's rapid advancements, the World ADC Event Series from Hanson Wade continues to provide unrivalled industry-focused insight and connections to accelerate the delivery of viable and life-changing therapeutics to oncology patients.
We share a common belief with the industry - that the potential of antibody-drug conjugates is enormous. In the war against cancer, ADCs can be a game-changer and we know that the right insights and connections can sharpen the weapons that are in your arsenal.
Get a comprehensive overview of the upcoming events within the World ADC Series below. If you have any questions, get in touch at adc@hansonwade.com.
The World's Definitive Antibody-Drug Conjugate Event Dedicated to Maximizing the Clinical Therapeutic Index of Your ADC

Driving Innovations in Linker & Conjugation Chemistries to Create Stable ADCs, with Low Aggregation & Controlled Release
at Scale
August 22 - 24, 2023 | Boston, MA

Enhancing ADC Process Development to Accelerate to First-In-Human Studies at Speed & Validating Robust Late Phase Processes for Commercial Preparedness
September 19 - 21, 2023 | Boston, MA
Transform ADC Target Selection Strategies Through Optimizing the Pairing of Target, Linker-Payload & Indication for Increased Efficacy, Tolerability & Clinical Outcomes
December 5 - 7, 2023 | Boston, MA
Pushing the Boundaries of Bioconjugate Drug Development With Next-Generation Payloads & Formats to Improve Translation & Show Clinical Proof-of-Concept
February 2024 | Boston, MA

Europe's Longest Standing & Definitive Antibody-Drug
Conjugate Event
March 2024 | London, UK

Optimizing the Application of Analytical Technologies for ADCs to Guide Regulatory Specifications & Submissions, Enhance Understanding of Your Drug & Exert Control Over Your Process
April 2024 | Boston, MA

Minimizing Toxicities & Improving Tolerability to Bring More ADCs With a Wider Therapeutic Index to Market
July 2024 | Boston, MA
Enhance Your ADC Knowledge Further
A manually curated database solution including clinical trials and drug records for preclinical, active, approved and discontinued drugs and treatments developed in partnership with the world's leading ADC drug developers and academics.
A vital year-round experience-sharing and problem-solving network to help drug developers make better ADC discovery decisions.
A trusted provider of market intelligence for anyone looking to understand the complexities of ADC and Engineered Antibodies research and development.
Not artificial, and not short-lived. We nurture the right environments in which people can communicate problems and solutions; share novel data and forge networks across the industry that will make each of your endeavors more informed and more robust.